TABLE 4.

Effect of once- or twice-daily T-705 treatment on an influenza A (H5N1) virus infection in mice

Expt no. and TreatmentaDosage (mg/kg/day)Toxicity controlsInfected, treated mice
No. of survivors/total no. testedMean host wt changeb (g)No. of survivors/total no. testeddMDDc ± SDdMean day 11 SaO2 (%) ± SDd
Expt 1
    T-705, once daily3003/30.410/10***>21.0***82.7 ± 2.4***
    T-705, once daily1003/30.410/10***>21.0***80.8 ± 2.0***
    T-705, once daily303/30.79/10**7.0 ± 0.081.4 ± 4.7***
    T-705, once daily103/30.64/107.3 ± 0.877.0 ± 2.8
    T-705, once daily33/30.30/107.0 ± 0.575.0 ± 0.0
    0.4% CMC7/207.5 ± 1.176.7 ± 2.7
    Healthy controls5/51.286.0 ± 3.8
Expt 2
    T-705, twice daily3003/30.210/10***>21.0***86.9 ± 2.8***
    T-705, twice daily1003/31.010/10***>21.0***84.2 ± 1.3***
    T-705, twice daily303/30.18/10***11.0 ± 4.279.8 ± 4.4***
    T-705, twice daily103/30.12/108.5 ± 2.875.5 ± 1.0*
    T-705, twice daily33/30.80/107.4 ± 1.175.0 ± 0.0
    0.4% CMC0/208.2 ± 1.675.0 ± 0.0
    Healthy controls5/50.585.6 ± 3.6
  • a Five-day treatments beginning 1 h after virus exposure.

  • b Difference between initial weight and weight 18 h after final treatment.

  • c MDD, mean day to death of mice dying prior to day 21.

  • d *, P < 0.05 compared to the results for the CMC-treated controls; **, P < 0.01 compared to the results for the CMC-treated controls; ***, P < 0.001 compared to the results for the CMC-treated controls.